DR. JEFFREY GLENN, M.D., PH.D.
Medical Practice at Miranda Ave, Palo Alto, CA
License number
California G080422
Category
Medical Practice
Type
Specialist
Address
Address
3801 Miranda Ave, Palo Alto, CA 94304
Phone
(650) 493-5000
Organization information
See more information about JEFFREY GLENN at bizstanding.comJeffrey Glenn MD,PHD
269 Campus Dr, Stanford, CA 94305
Industry:
Internist
Phone:
(650) 725-3373 (Phone)
Jeffrey Scott Glenn
Professional information
Methods And Compositions For Identifying Anti-Hcv Agents
US Patent:
7582428, Sep 1, 2009
Filed:
Aug 18, 2004
Appl. No.:
10/528377
Inventors:
Jeffrey S. Glenn - Palo Alto CA, US
Shirit Einav - Stanford CA, US
Menashe Elazar - Palo Alto CA, US
Shirit Einav - Stanford CA, US
Menashe Elazar - Palo Alto CA, US
Assignee:
The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA
International Classification:
C12Q 1/68, C12Q 1/00
US Classification:
435 6, 435 4, 435 5
Abstract:
The invention provides methods and compositions for identifying agents for treating infection by viruses that encode a nucleotide-binding NS4B protein, or functional equivalent thereof, e. g. , hepatitis C virus (HCV) or other members of the family Flaviviridae. In general, the methods involve contacting an NS4B nucleotide binding motif (NBM)-containing polypeptide with a candidate agent, and determining the effect of the candidate agent on nucleotide binding activity, a nucleotide hydrolyzing activity, or a nucleotide-dependent RNA binding activity of the polypeptide. A candidate agent that inhibits NS4B polypeptide binding to a nucleotide is an anti-viral agent, e. g. , an anti-HCV agent. The invention also features a polynucleotide encoding a NS4B polypeptide having a modified NBM (e. g. , which is impaired in NTP binding).
Method Of Fabricating Lipid Bilayer Membranes On Solid Supports
US Patent:
8211712, Jul 3, 2012
Filed:
Mar 29, 2006
Appl. No.:
11/887669
Inventors:
Nam-Joon Cho - Stanford CA, US
Curtis W. Frank - Cupertino CA, US
Jeffrey S. Glenn - Palo Alto CA, US
Kwang Ho Cheong - Giheung-Gu, KR
Curtis W. Frank - Cupertino CA, US
Jeffrey S. Glenn - Palo Alto CA, US
Kwang Ho Cheong - Giheung-Gu, KR
Assignee:
The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA
International Classification:
G01N 33/543
US Classification:
436518
Abstract:
The present invention provides a method of producing a planar lipid bilayer on a solid support. With this method, a solution of lipid vesicles is first deposited on the solid support. Next, the lipid vesicles are destabilized by adding an amphipathic peptide solution to the lipid vesicle solution. This destabilization leads to production of a planar lipid bilayer on the solid support. The present invention also provides a supported planar lipid bilayer, where the planar lipid bilayer is made of naturally occurring lipids and the solid support is made of unmodified gold or titanium oxide. Preferably, the supported planar lipid bilayer is continuous. The planar lipid bilayer may be made of any naturally occurring lipid or mixture of lipids, including, but not limited to phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinsitol, cardiolipin, cholesterol, and sphingomyelin.
Agents For Treatment Of Hcv And Methods Of Use
US Patent:
2012009, Apr 19, 2012
Filed:
Dec 15, 2011
Appl. No.:
13/326793
Inventors:
Jeffrey S. Glenn - Palo Alto CA, US
Tina Marie Myers - Indianapolis IN, US
John Irvin Glass - Germantown MD, US
Tina Marie Myers - Indianapolis IN, US
John Irvin Glass - Germantown MD, US
International Classification:
A61K 39/29, C12Q 1/70, A61P 31/14, A61K 38/16, C07K 14/18, C07H 21/02
US Classification:
4241891, 530324, 536 2372, 530326, 514 43, 435 5
Abstract:
An amphipathic helix at the approximate N-terminus of Hepatitis C virus (HCV) nonstructural proteins mediates the association of these proteins with cytoplasmic membranes in infected cells. This association is essential for replication. Thus, assessing the ability of compounds or protocols to disrupt the association of such helices with cytoplasmic membranes permits identification of compounds and protocols which are useful in the treatment of HCV infection. Also useful in the invention are mimics, or function-disrupting ligands, of an amphipathic helix of the nonstructural proteins described herein and antibodies and fragments thereof immunoreactive with said helix.
Agents For Treatment Of Hcv And Methods Of Use
US Patent:
8093353, Jan 10, 2012
Filed:
Sep 4, 2007
Appl. No.:
11/899393
Inventors:
Jeffrey S. Glenn - Palo Alto CA, US
Tina Marie Myers - Indianapolis IN, US
John Irvin Glass - Germantown MD, US
Tina Marie Myers - Indianapolis IN, US
John Irvin Glass - Germantown MD, US
Assignee:
The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA
Eli Lilly and Company - Indianapolis IN
Eli Lilly and Company - Indianapolis IN
International Classification:
C07K 5/00
US Classification:
530300, 4242181
Abstract:
An amphipathic helix at the approximate N-terminus of Hepatitis C virus (HCV) nonstructural proteins mediates the association of these proteins with cytoplasmic membranes in infected cells. This association is essential for replication. Thus, assessing the ability of compounds or protocols to disrupt the association of such helices with cytoplasmic membranes permits identification of compounds and protocols which are useful in the treatment of HCV infection. Also useful in the invention are mimics, or function-disrupting ligands, of an amphipathic helix of the nonstructural proteins described herein and antibodies and fragments thereof immunoreactive with said helix.
Methods And Compositions Of Treating A Flaviviridae Family Viral Infection
US Patent:
2010001, Jan 21, 2010
Filed:
Mar 18, 2009
Appl. No.:
12/383071
Inventors:
Shirit Einav - Stanford CA, US
Jeffrey S. Glenn - Palo Alto CA, US
Wenjin Yang - Foster City CA, US
Ingrid C. Choong - Palo Alto CA, US
Robert McDowell - San Francisco CA, US
Jeffrey S. Glenn - Palo Alto CA, US
Wenjin Yang - Foster City CA, US
Ingrid C. Choong - Palo Alto CA, US
Robert McDowell - San Francisco CA, US
International Classification:
A61K 38/21, A61K 31/416, C12N 5/00, C07D 231/56, C07D 401/12, A61K 31/454, A61P 31/12, C07D 403/12
US Classification:
424 857, 514403, 435377, 424 854, 5483611, 546199, 514322
Abstract:
Briefly described, embodiments of this disclosure include compounds, pharmaceutical compositions, methods of treating a host infected with a virus from the Flaviviridae family of viruses, methods of inhibiting HCV replication in a host, methods of inhibiting the binding of NS4B polypeptide to the 3′UTR of HCV negative strand RNA in a host, methods of treating liver fibrosis in a host, and the like.
Amphipathic Alpha-Helical Peptide Compositions As Antiviral Agents
US Patent:
2009010, Apr 23, 2009
Filed:
Jul 14, 2008
Appl. No.:
12/172796
Inventors:
Jeffrey Glenn - Palo Alto CA, US
Nam-Joon Cho - Stanford CA, US
Curtis W. Frank - Cupertino CA, US
Kwang Ho Cheong - Yongin-Si, KR
Nam-Joon Cho - Stanford CA, US
Curtis W. Frank - Cupertino CA, US
Kwang Ho Cheong - Yongin-Si, KR
International Classification:
A61K 38/10, C12N 7/00, A01N 1/02
US Classification:
514 14, 435238, 435 2
Abstract:
The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.
Methods And Compositions Of Treating A Flaviviridae Family Viral Infection
US Patent:
2012014, Jun 14, 2012
Filed:
Mar 16, 2010
Appl. No.:
13/376486
Inventors:
Jeffrey S. Glenn - Palo Alto CA, US
Wenjin Yang - Foster City CA, US
Ingrid C. Choong - Los Altos CA, US
Wenjin Yang - Foster City CA, US
Ingrid C. Choong - Los Altos CA, US
International Classification:
A61K 38/21, A61K 31/454, C07D 403/12, A61K 31/416, C07D 231/56, C07D 413/14, A61K 31/5377, A61K 31/55, C07D 401/14, A61K 31/4439, C07D 405/14, C07D 403/14, A61K 31/506, C07D 491/08, A61K 31/7056, A61P 31/14, C07D 401/12
US Classification:
424 857, 546199, 514322, 5483615, 514407, 544124, 5142345, 540603, 51421709, 5462757, 514338, 544331, 514275, 424 854, 514 43
Abstract:
Briefly described, embodiments of this disclosure include compounds, pharmaceutical compositions, methods of treating a host infected with a virus from the Flaviviridae family of viruses, methods of inhibiting HCV replication in a host, methods of inhibiting the binding of NS4B polypeptide to the 3′UTR of HCV negative strand RNA in a host, methods of treating liver fibrosis in a host, and the like.
Methods And Compositions Of Treating A Flaviviridae Family Viral Infection
US Patent:
2012027, Nov 1, 2012
Filed:
Mar 16, 2010
Appl. No.:
13/376483
Inventors:
Ingrid C. Choong - Los Altos CA, US
David Cory - Redwood City CA, US
Jeffrey S. Glenn - Palo Alto CA, US
Wenjin Yang - Foster City CA, US
David Cory - Redwood City CA, US
Jeffrey S. Glenn - Palo Alto CA, US
Wenjin Yang - Foster City CA, US
International Classification:
A61K 31/4184, A61K 38/21, A61P 31/14, C07D 403/06, C07D 405/14, C07D 401/06, A61K 31/454, C07D 451/02, A61K 31/46, A61K 31/4439, C07D 409/06, C07D 401/12, C07D 401/14, A61K 31/55, C07D 235/08, C07D 235/14, A61K 31/7056
US Classification:
424 857, 514394, 514 43, 5483061, 546199, 514322, 546126, 514304, 5462734, 514338, 5483047, 540603, 51421709
Abstract:
Clemizole and clemizole analog compounds, and pharmaceutical compositions of the same, are useful in methods of treating a host infected with a virus from the Flaviviridae family of viruses, methods of inhibiting HCV replication in a host, methods of inhibiting the binding of NS4B polypeptide to the 3′UTR of HCV negative strand RNA in a host, and methods of treating liver fibrosis in a host.
Methods And Compositions Of Treating A Flaviviridae Family Viral Infection
US Patent:
2010002, Feb 4, 2010
Filed:
Mar 18, 2009
Appl. No.:
12/383030
Inventors:
Shirit Einav - Stanford CA, US
Jeffrey S. Glenn - Palo Alto CA, US
Wenjin Yang - Foster City CA, US
Ingrid C. Choong - Palo Alto CA, US
Robert McDowell - San Francisco CA, US
Jeffrey S. Glenn - Palo Alto CA, US
Wenjin Yang - Foster City CA, US
Ingrid C. Choong - Palo Alto CA, US
Robert McDowell - San Francisco CA, US
International Classification:
A61K 38/21, A61K 31/4184, C07D 403/02, C07D 403/12, C07D 471/04, A61K 31/497, A61K 31/4439, A61K 31/708, A61P 31/12
US Classification:
424 857, 514394, 5483061, 544370, 546118, 51425406, 514303, 514 43
Abstract:
Briefly described, embodiments of this disclosure include compounds, pharmaceutical compositions, methods of treating a host infected with a virus from the Flaviviridae family of viruses, methods of inhibiting HCV replication in a host, methods of inhibiting the binding of NS4B polypeptide to the 3′UTR of HCV negative strand RNA in a host, methods of treating liver fibrosis in a host, and the like.
Antiviral Compounds
US Patent:
5605828, Feb 25, 1997
Filed:
May 16, 1995
Appl. No.:
8/442322
Inventors:
Jeffrey S. Glenn - Palo Alto CA
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
C12N 704, A01N 4372, A01N 4390
US Classification:
435236
Abstract:
The macrolide FK506, produced by Fujisawa Pharmaceuticals is effective in inhibiting the replication of hepatitis D virus. It is believed that replication is inhibited either by virtue of the ability of FK506 to inhibit proline isomerase or otherwise to interfere with the function of a C-terminal proline in a replication factor or by virtue of its interference with RNA replication directly.